A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open-label, single-arm phase II study to evaluate efficacy,
safety, and pharmacokinetics characteristics of HA121-28 tablets in advanced biliary tract
cancer (BTC). A total of approximately 30 subjects with advanced BTC will be enrolled. The
subjects will undergo a 3 weeks-on and 1week-off treatment scheme with HA121-28 tablets 600
mg orally once daily in the 28-day cycle until disease progression or intolerable toxic
reaction, whichever occurs first.